BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Nov 15, 2018
Politics & Policy

Brexit deal smooths transition for MAAs, IP protections

Details of a draft Brexit deal reveal that the U.K.'s MHRA and EMA will be able to share MAA dossiers and both sides will honor IP protections during a transition period set to run until...
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jan 31, 2018
Distillery Therapeutics


...Brain cancer; breast cancer; colorectal cancer Cell culture and mouse studies identified an indole-quinoline-based dual PIP4K2A/PIP4K2C...
...the compound had no effect. Additional in vitro and cell-based binding and activity assays identified PIP4K2A...
...the compound in additional models of Ras-driven cancer. TARGET/MARKER/PATHWAY: Ras; phosphatidylinositol-5-phosphate 4-kinase type II α (PIP4K2A...
BioCentury | Jan 17, 2018
Distillery Therapeutics


INDICATION: Huntington's disease (HD) Patient sample, mouse and fruit fly studies suggest inhibiting PIP4K2C could help treat HD. In two fibroblast cell lines derived from HD patients and neurons from a mouse model of HD,...
BioCentury | Jan 20, 2017
Company News

PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of...
BioCentury | Oct 17, 2016

Accounting for input

More than many HTA bodies, NICE has a reputation for seeking patient input throughout the process of conducting a health technology appraisal. But patient groups say it isn't clear whether or how this input affects...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase class 2 subunit β polypeptide (PI3KC2B); myotubularin 1 (MTM1); phosphatidylinositol-3-phosphate (PI3P)

Musculoskeletal disease INDICATION: Musculoskeletal Mouse and zebrafish studies suggest inhibiting PI3KC2B could help treat myotubular myopathy, which is caused by mutations in MTM1 . In a mouse model of the disease, muscle-specific knockout of PI3KC2B or...
BioCentury | Jul 25, 2016
Company News

Sprint Bioscience deal

...Sprint granted an undisclosed U.S. company worldwide rights to develop and commercialize Sprint’s phosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A) inhibitor program...
BioCentury | Jan 25, 2016
Company News

PharmAthene, Siga infectious news

The Delaware Supreme Court affirmed a January 2015 Court of Chancery ruling ordering Siga to pay PharmAthene about $195 million in a case involving Siga’s Tecovirimat ( ST-246 ). Siga filed a plan of reorganization with...
Items per page:
1 - 10 of 162